Extended Data Fig. 2: Longitudinal changes in CSF biomarkers across treatment arms.
Box plots showing the annual percent change of a) secondary and b) pre-specified exploratory CSF biomarkers in the placebo (salmon), 200 mg LM11A-31 (green) and 400 mg LM11A-31 (blue) groups. Horizontal lines on box plots represent the median of the distribution. Notches provide 95% confidence intervals of the median, which represent the reliability of within-group change. The lower and upper hinges of the boxplot correspond to the first and third quartiles of the distribution, and the whiskers (vertical lines) extend from the hinge to the largest or smallest value, no further than ±1.5 times the interquartile range from the hinge. Significant Kruskal-Wallis tests (PAChE = 0.029; PAβ40 = 0.015; PAβ42 = 0.032; PSNAP25 = 0.035; PNG = 0.024) were followed by post hoc Dunn’s tests to determine which groups differed significantly from each other. The number of participants included in each statistical test varied due to availability of test results for a given subject and variation in outlier number (3-12 per variable across all trial participants). Sample sizes are indicated below each boxplot. All statistics were performed two-sided and were not adjusted for multiple comparisons, given the exploratory nature of the study. Aβ42/40, ratio of Aβ42 to Aβ40.
